An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853).

Trial Profile

An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853).

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 30 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top